JP6307149B2 - 癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー - Google Patents

癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー Download PDF

Info

Publication number
JP6307149B2
JP6307149B2 JP2016504349A JP2016504349A JP6307149B2 JP 6307149 B2 JP6307149 B2 JP 6307149B2 JP 2016504349 A JP2016504349 A JP 2016504349A JP 2016504349 A JP2016504349 A JP 2016504349A JP 6307149 B2 JP6307149 B2 JP 6307149B2
Authority
JP
Japan
Prior art keywords
cells
tumor
compound
trail
ahl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016504349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515546A (ja
JP2016515546A5 (https=
Inventor
ウラジーミル クラブチェンコ
ウラジーミル クラブチェンコ
リチャード ジェイ． ウレビッチ
リチャード ジェイ． ウレビッチ
キム ディー． ヤンダ
キム ディー． ヤンダ
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2016515546A publication Critical patent/JP2016515546A/ja
Publication of JP2016515546A5 publication Critical patent/JP2016515546A5/ja
Application granted granted Critical
Publication of JP6307149B2 publication Critical patent/JP6307149B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016504349A 2013-03-19 2014-03-19 癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー Expired - Fee Related JP6307149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803177P 2013-03-19 2013-03-19
US61/803,177 2013-03-19
PCT/US2014/031235 WO2014153415A2 (en) 2013-03-19 2014-03-19 Trail enhancers for the selective killing of cancer cells

Publications (3)

Publication Number Publication Date
JP2016515546A JP2016515546A (ja) 2016-05-30
JP2016515546A5 JP2016515546A5 (https=) 2017-05-25
JP6307149B2 true JP6307149B2 (ja) 2018-04-04

Family

ID=51581796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504349A Expired - Fee Related JP6307149B2 (ja) 2013-03-19 2014-03-19 癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー

Country Status (8)

Country Link
US (2) US9604950B2 (https=)
EP (1) EP2976076B1 (https=)
JP (1) JP6307149B2 (https=)
KR (2) KR101819874B1 (https=)
CN (1) CN105228618A (https=)
AU (1) AU2014236003A1 (https=)
CA (1) CA2907668C (https=)
WO (1) WO2014153415A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells
US10195177B2 (en) 2015-10-01 2019-02-05 The University Of Toledo Use of acyl-homoserine lactone derivatives as anti-thrombotic agents
CN105504000B (zh) * 2016-01-21 2019-06-07 福建农林大学 一种筛选n-酰基高丝氨酸内酯类模拟物的方法
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
EP3666908A1 (en) * 2016-06-03 2020-06-17 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN110935012A (zh) * 2019-12-19 2020-03-31 东北师范大学 一种用于治疗肿瘤的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924195D0 (en) * 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
JP2004231556A (ja) * 2003-01-29 2004-08-19 Nobuhiko Nomura アポトーシス誘導剤
WO2004075839A2 (en) * 2003-02-21 2004-09-10 Irm Llc Methods and compositions for modulating apoptosis
US20070010477A1 (en) * 2005-04-07 2007-01-11 Dolnick Bruce J Acyl homoserine lactones for inhibition of cell growth
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
GB0610042D0 (en) * 2006-05-22 2006-06-28 Univ Nottingham Substituted n-acyl homoserine lactones
EP2448930B1 (en) * 2009-07-03 2017-02-15 The National Institute for Biotechnology in the Negev Ltd. N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells

Also Published As

Publication number Publication date
KR101819874B1 (ko) 2018-01-17
US9765061B2 (en) 2017-09-19
KR101743383B1 (ko) 2017-06-02
US20160272603A1 (en) 2016-09-22
CN105228618A (zh) 2016-01-06
US20170101400A1 (en) 2017-04-13
US9604950B2 (en) 2017-03-28
EP2976076A4 (en) 2016-11-16
EP2976076B1 (en) 2020-03-04
CA2907668C (en) 2021-02-23
JP2016515546A (ja) 2016-05-30
CA2907668A1 (en) 2014-09-25
WO2014153415A3 (en) 2015-01-08
WO2014153415A2 (en) 2014-09-25
KR20150135387A (ko) 2015-12-02
KR20170063980A (ko) 2017-06-08
AU2014236003A1 (en) 2015-11-05
EP2976076A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
JP6307149B2 (ja) 癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
Facchini et al. Structure–activity relationship in monosaccharide-based toll-like receptor 4 (TLR4) antagonists
TWI830875B (zh) 化合物在製備用於抑制激酶之組合物的用途
US20090306201A1 (en) Selective inhibitors for transferases
BG63944B1 (bg) Производни на хидроксиламина, които се използват за повишаване продуцирането на молекулен чаперон исъстав
Kazakova et al. From marine metabolites to the drugs of the future: squalamine, trodusquemine, their steroid and triterpene analogues
Ivanenkov et al. New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways
JP2018534301A (ja) 新規ガラクトシドによるガレクチン阻害剤
JP2020189857A (ja) イカリイン誘導体
JP2024010082A (ja) オートファジーおよびリポファジーを調節するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
Singla et al. Facially amphiphilic cholic acid–lysine conjugates as promising antimicrobials
JP2023126633A (ja) Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法
Haygood et al. Niclosamide analogs for treatment of ovarian cancer
WO2015153653A1 (en) Arylnaphthalene lactone derivatives and methods of making and using thereof
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
EP4444274A1 (en) Compositions comprising modified phospholipids and uses thereof
US20160113900A1 (en) Inhibitors of mitochondrial stat3 and uses thereof in modulation of mast cell exocytosis
JP2021535170A (ja) 薬物送達のための相乗的な透過促進剤を伴う組成物
Zeng et al. Structure–activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway
Zhang et al. Ocotillol derivatives mitigate retinal ischemia-reperfusion injury by regulating the Keap1/Nrf2/ARE signaling pathway
WO2025079163A1 (ja) ４－（２，４－ジフルオロフェニル）－２－（１ｈ－インドール－３－イル）－４－オキソ－ブタン酸のｓ（＋）体
TW202440134A (zh) 新穎小分子kras抑制劑：為難成藥標的提供藥物用於癌症治療
OA21266A (en) Dicarboxylic acid esters for inducing an analgesic effect.
Samadi et al. Autotaxin and lysophosphatidate produce chemoresistance by releasing breast cancer cells from Taxol-induced mitotic arrest

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170406

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180309

R150 Certificate of patent or registration of utility model

Ref document number: 6307149

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees